BTLA and renal cell adenocarcinoma: HVEM is a ligand of B- and T-lymphocyte attenuator (BTLA) and soluble BTLA in combination with sTIM-3 may be able to predict the rates of disease recurrence and survival among renal cell cancer patients [48].